Claims
- 1. A method for inhibiting proliferation and survival of pre-cancerous and cancerous cells comprising the steps of:
selecting a composition containing 2-methoxyestradiol; and administering said composition to a cellular aggregation in which is identified suspected pre-cancerous or cancer cells.
- 2. The method of claim 1 wherein said suspected pre-cancerous or cancer cells are related to human prostate cancer.
- 3. The method of claim 1 wherein said suspected pre-cancerous or cancer cells are related to human nervous system cancer.
- 4. The method of claim 1 wherein said suspected pre-cancerous or cancer cells are related to human skin cancer.
- 5. A method for inhibiting proliferation and survival of pre-cancerous and cancerous cells comprising the steps of:
selecting a composition consisting substantially of one or more of 2-methoxy estradiol,2-ethoxyestradiol,2-butoxyestradiol, 17-α-ethynylestradiol with methoxy group at position 2,17-α-ethynylestradiol with butoxy group at position 2, 17-α-ethynyl-9-α-fluoroestradiol with methoxy group at position 2; and 17-α-ethynyl-9-α-fluoroestradiol with butoxy group at position 2. administering said composition to a cellular aggregation in which is identified suspected said pre-cancerous or cancerous cells.
- 6. The method of claim 5 wherein said suspected pre-cancerous or cancerous cells are prostatic cancer cells.
- 7. A composition for application to cellular aggregation containing pre-cancerous or cancerous cells consisting in active constituents substantially of one or more agents chosen from a groups consisting of 2-methoxyestradiol,2-ethoxyestradiol,2butoxyestradiol, 17-α-ethynylestradiol with methoxy group at position 2, 17-α-ethynylestradiol with butoxy group at position 2, 17-α-ethynyl-9-α-fluoroestradiol with methoxy group at position 2; and 17-α-ethynyl-9-α-fluoroestradiol with butoxy group at position 2.
- 8. The composition of claim 7 wherein said pre-cancerous or cancerous cells are related to prostate cancer.
- 9. The use of compositions useful in the inhibition of pre-cancerous or cancerous cell proliferation and cell survival selected from a group consisting essentially of:
the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol; the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8; the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8; the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9; the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6; the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6; and the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7.
- 10. The method of claim 9 wherein said pre-cancerous or cancerous cells are related to brain cancer.
- 11. The method of claim 9 wherein said pre-cancerous or cancerous cells are related to prostate cancer.
- 12. The method of claim 9 wherein said pre-cancerous or cancerous cells are related to skin cancer.
- 13. The method of claim 9 wherein said pre-cancerous or cancerous cells are related to lung cancer.
- 14. The method of claim 9 wherein said pre-cancerous or cancerous cells are related to colon cancer.
- 15. A method for inhibiting pre-cancerous or cancerous cell proliferation comprising the steps of:
selecting a composition from the group consisting of the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7; and administering said composition to cells in which is identified suspected pre-cancerous or cancer cells.
- 16. The method of claim 15 wherein said suspected pre-cancerous or cancerous cells are related to cancers of the nervous system.
- 17. The method of claim 15 wherein said suspected pre-cancerous or cancerous cells are related to prostate cancer.
- 18. The method of claim 15 wherein said suspected pre-cancerous or cancerous cells are related to pernicious mitosis of skin cells.
- 19. The method of claim 15 wherein said suspected pre-cancerous or cancerous cells are related to cancers of the colon.
- 20. A composition for application to pre-cancerous or cancerous cells consisting in active constituents substantially of one or more agents chosen from the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol, the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8, the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8, the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9, the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6, the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6, or the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7.
- 21. The method of claim 20 wherein said pre-cancerous or cancerous cells are related to brain cancer.
- 22. The method of claim 20 wherein said pre-cancerous or cancerous cells are related to skin cancer.
- 23. The method of claim 20 wherein said pre-cancerous or cancerous cells are related to human prostate cancer.
- 24. A method for preventing the onset of cancer and for preventing the recurrence of cancer comprising the administration of a therapeutic dose to a human recipient of one or more compositions selected from the group consisting of:
2-methoxyestradiol;; the 2-ethyl-17-β-estradiol molecules identified as analogues 20-22 in FIG. 8, specifically excluding any claim to 2-methyloxyestradiol; the 17-α-ethynyl molecules identified as analogues 23-26 in FIG. 8; the 17-α-ethyl molecules identified as analogues 27-30 in FIG. 8; the 2,3-methylenedioxy molecules identified as analogues 31, 32, and 33 in FIG. 9; the 2-alkoxy substituted analogues of estrone molecules identified as analogues 8-10 in FIG. 6; the 2-ethyl substituted molecule identified as analogue 14 in FIG. 6; and the 2,3-methylenedioxyestrone molecule identified as analogue 18 in FIG. 7.
- 25. The method of claim 24 wherein a therapuetic dose of eugenol is administered in conjunction with said one or more compositions.
- 26. The method of claim 24 wherein said cancer is human prostate cancer.
- 27. The method of claim 24 wherein said cancer is human nervous system cancer.
- 28. The method of claim 24 wherein said cancer is human skin cancer.
- 29. The method of claim 24 wherein said cancer is human colon cancer.
- 30. The method of claim 25 wherein said cancer is human prostate cancer.
- 31. The method of claim 25 wherein said cancer is human nervous system cancer.
- 32. The method of claim 25 wherein said cancer is human skin cancer.
- 33. The method of claim 25 wherein said cancer is human colon cancer.
- 34. A method of inducing apoptosis in cancerous tissues comprising the steps of:
administering a therapeutic dosage of a composition containing 2-methoxyestradiol to a cancerous tissues, said administration continuing at least until the initiation of cell apoptosis in said cancerous tissues.
- 35. A method for arresting growth of cancer tissues comprising the steps of:
administering a therapeutic dosage of a composition containing 2-methoxyestradiol to a cancerous tissue, said administration occurring at a time which, at least for some cells in said cancerous tissue, precedes cell division in the G2/M phase.
CITATION TO PRIOR APPLICATION
[0001] This is a continuation of PCT/US 0,108,718 (published in English on Sep. 17, 2001—International Publication No. WO 01/70093 A2) designating the United States and with an International Filing Date of Mar. 19, 2001, and a Priority Date of Mar. 17, 2000 (based on U.S. application Ser. No. 09,527,283, now abandoned). This is also a continuation-in-part of co-pending U.S. application Ser. No. 09,780,269, filed Feb. 9, 2001, and of co-pending U.S. application Ser. No. 09,777,151, filed Feb. 5, 2001. Applicant claims priority, as applicable, pursuant to 35 U.S.C. §§ 119-120, and as provided under the Patent Cooperation Treaty.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/08718 |
Mar 2001 |
US |
Child |
10245775 |
Sep 2002 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09780269 |
Feb 2001 |
US |
Child |
10245775 |
Sep 2002 |
US |
Parent |
09777151 |
Feb 2001 |
US |
Child |
10245775 |
Sep 2002 |
US |